Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Behavioral effects of new third-generation SERM and known nonsteroidal ER ligands

July 20, 1999

Roche claims another series acting as OFQ receptor antagonists

July 20, 1999

Ligands for histamine H3 receptors in the pipeline at Sanofi-Synthelabo

July 19, 1999

Gabapentin found to reduce symptoms of social anxiety disorder

July 19, 1999

New non-narcotic analgesic/antiinflammatory agent emerges from Ukraine

July 16, 1999

Novel opioid analgesic HS-599 operating at the spinal level presented in Budapest

July 16, 1999

Gidazepam exerts differential anxiolytic effects depending on individual reaction to stress

July 15, 1999

Double-strength formulation of Esterom to be tested in phase III

July 15, 1999

SB discovers new class of compounds with high affinity for several 5-HT receptor subtypes

July 15, 1999

ABT-431: the first D1 agonist with demonstrated antiparkinsonian activity in patients

July 14, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...